Previous 10 | Next 10 |
AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will become effective prior to market open on Monday, December 23, 2019. T...
Shares of XBiotech (NASDAQ: XBIT) more than doubled today after the tiny company agreed to sell its lead drug candidate, bermekimab, to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen for $750 million up front and up to $600 million in potential milestone payments. XBiotech will als...
Gainers: Synthorx (NASDAQ: THOR ) +170% . More news on: Synthorx, Inc., ArQule, Inc., Forty Seven, Inc., Stocks on the move, Read more ...
Synthorx (NASDAQ: THOR ) +169% on being acquired by Sanofi. More news on: Synthorx, Inc., XBiotech Inc., ArQule, Inc., Stocks on the move, Read more ...
XBiotech (NASDAQ: XBIT ) inks an agreement with Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab. More news on: XBiotech Inc., Johnson & Johnson, Healthcare stocks news, Stocks on the move, Read more ...
XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today...
Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS AUSTIN, Texas, Nov. 19, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announces rapid enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical study eva...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 131 weeks of public selections as part of this ongoing live forward-testing. In...
AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking antibody therapy in patients with moderate to severe Atopic Dermatitis (AD) (a...
Enrollment is underway in a Phase 2 clinical trial evaluating XBiotech's ( XBIT -0.3% ) bermekimab in patients with hidradenitis suppurativa, a condition characterized by small painful lumps under the skin, typically in area where skin rubs together (e.g., armpits, groin, buttocks, br...
News, Short Squeeze, Breakout and More Instantly...
2024-03-28 02:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-26 19:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site pre...